FIGURE 6.

Fibroblast growth factor receptor 4 (FGFR4) increases cell viability against epidermal growth factor receptor inhibition in colon cancer cells. A, Colon cancer cells with FGFR4 expression or vector control plasmid were treated with different concentrations of cetuximab (range, 31‐500 μg/mL) for 48 h and cell viability were evaluated. *P < .05 compared to each vector control. B, Different concentrations of BLU9931 (range, 0.63‐40 μmol/L) were used to treat cancer cells for 48 h and cell viability were evaluated. C, Cells were treated with 250 μg/mL cetuximab, 5 μmol/L BLU9931, or their combination for 48 h and cell viability were evaluated. D, Kaplan‐Meier survival analysis for FGFR4 and amphiregulin (AREG) expression was carried out in 63 patients with metastatic colon cancer treated with cetuximab. Data are presented as mean ± SD. **P < .01, ***P < .001